sub:assertion {
  d:DB05332 v:identifier "DB05332" ;
    v:namespace "drugbank" ;
    v:uri "http://bio2rdf.org/drugbank:DB05332" ;
    v:x-identifiers.org <http://identifiers.org/drugbank/DB05332> ;
    dv:drugbank-id "DB05332" ;
    dv:x-atc <http://bio2rdf.org/atc:B02BX04> ;
    dv:x-cas <http://bio2rdf.org/cas:267639-76-9> ;
    dv:x-kegg <http://bio2rdf.org/kegg:D08990> ;
    dv:x-ndc <http://bio2rdf.org/ndc:55513-221-01> ;
    dv:x-wikipedia <http://bio2rdf.org/wikipedia:Romiplostim> ;
    dct:description "Romiplostim is a thrombopoiesis stimulating dimer Fc-peptide fusion protein (peptibody) to increase platelet production through activation of the thrombopoietin receptor. The peptibody molecule has two identical single-chain subunits, each one is made up of 269 amino acid residues. Each subunit consists of an IgG1 Fc carrier domain that is covalently attached to a polypeptide sequence that contains two binding domains to interact with thrombopoietin receptor c-Mpl. Each domain consists of 14 amino acids. Interestingly, romiplostim's amino acid sequence is not similar to that of endogenous thrombopoietin. Romiplostim is produced by recombinant DNA technology in Escherichia coli. FDA approved on August 22, 2008."@en ;
    dct:identifier "drugbank:DB05332" ;
    dct:title "Romiplostim"@en ;
    a dv:Drug ;
    rdfs:label "Romiplostim [drugbank:DB05332]"@en ;
    rdfs:seeAlso <http://www.drugbank.ca/drugs/DB05332> , <http://www.drugs.com/monograph/romiplostim.html> , <http://www.rxlist.com/nplate-drug.htm> .
}